Abstract
Rosuvastatin (RS) is a statin medication used to lower cholesterol levels and reduce the risk of cardiovascular diseases. RS works by inhibiting an enzyme called HMG-CoA reductase, which helps decrease LDL cholesterol and increase HDL cholesterol. The typical dose range for rosuvastatin is 5-40 mg once daily, with the starting dose usually being 10 mg. However, the dosage may vary depending on the patient's cholesterol levels and individual response to the medication. Rosuvastatin has a half-life of approximately 19 hours and undergoes metabolism mainly in the liver. The aim of the study was to develop a transdermal patch containing Rosuvastatin in the form of niosomes (NP). The Rosuvastatin niosomes were prepared using the solvent casting method, and the optimized formulation showed a particle size of 211.6 nm with a polydispersity index (PDI) of 0.197. The zeta potential of the niosomes was found to be -44.7. These results indicate that the developed formulation has a uniform particle size distribution and a stable zeta potential, which are important factors for the effective delivery of Rosuvastatin through a transdermal patch. Invitro diffusion studies of the optimized patch RN-T6 released upto 24 hours with %CDR of 98.98% and the drug diffusion data is fitted into various mathematical models and RN-T6 followed zero order drug release kinetics and the diffusion mechanism was non-fickian diffusion.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
